These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 31959131)

  • 1. IL-1-conferred gene expression pattern in ERα
    Nawas AF; Kanchwala M; Thomas-Jardin SE; Dahl H; Daescu K; Bautista M; Anunobi V; Wong A; Meade R; Mistry R; Ghatwai N; Bayerl F; Xing C; Delk NA
    BMC Cancer; 2020 Jan; 20(1):46. PubMed ID: 31959131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-1β induces p62/SQSTM1 and represses androgen receptor expression in prostate cancer cells.
    Chang MA; Patel V; Gwede M; Morgado M; Tomasevich K; Fong EL; Farach-Carson MC; Delk NA
    J Cell Biochem; 2014 Dec; 115(12):2188-97. PubMed ID: 25103771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth.
    Aakula A; Leivonen SK; Hintsanen P; Aittokallio T; Ceder Y; Børresen-Dale AL; Perälä M; Östling P; Kallioniemi O
    Mol Oncol; 2015 Aug; 9(7):1287-300. PubMed ID: 25907805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence.
    Dahl HC; Kanchwala M; Thomas-Jardin SE; Sandhu A; Kanumuri P; Nawas AF; Xing C; Lin C; Frigo DE; Delk NA
    PLoS One; 2020; 15(12):e0242970. PubMed ID: 33326447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of an IL-1-induced gene expression pattern in AR
    Thomas-Jardin SE; Kanchwala MS; Jacob J; Merchant S; Meade RK; Gahnim NM; Nawas AF; Xing C; Delk NA
    Prostate; 2018 Jun; 78(8):595-606. PubMed ID: 29527701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
    Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
    Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
    Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
    Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-1 induces p62/SQSTM1 and autophagy in ERα
    Nawas AF; Mistry R; Narayanan S; Thomas-Jardin SE; Ramachandran J; Ravichandran J; Neduvelil E; Luangpanh K; Delk NA
    J Cell Biochem; 2019 Feb; 120(2):1477-1491. PubMed ID: 30324661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the androgen receptor in prostate and breast cancer: several new agents in development.
    Proverbs-Singh T; Feldman JL; Morris MJ; Autio KA; Traina TA
    Endocr Relat Cancer; 2015 Jun; 22(3):R87-R106. PubMed ID: 25722318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-190 enhances endocrine therapy sensitivity by regulating SOX9 expression in breast cancer.
    Yu Y; Yin W; Yu ZH; Zhou YJ; Chi JR; Ge J; Cao XC
    J Exp Clin Cancer Res; 2019 Jan; 38(1):22. PubMed ID: 30658681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor and estrogen receptor variants in prostate and breast cancers.
    Valentín López JC; Lange CA; Dehm SM
    J Steroid Biochem Mol Biol; 2024 Jul; 241():106522. PubMed ID: 38641298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.
    Cai C; Wang H; He HH; Chen S; He L; Ma F; Mucci L; Wang Q; Fiore C; Sowalsky AG; Loda M; Liu XS; Brown M; Balk SP; Yuan X
    J Clin Invest; 2013 Mar; 123(3):1109-22. PubMed ID: 23426182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines.
    Marques RB; Dits NF; Erkens-Schulze S; van Ijcken WF; van Weerden WM; Jenster G
    PLoS One; 2011; 6(8):e23144. PubMed ID: 21829708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR2-triggered autophagy and activation of Nrf-2 reduce breast cancer cell response to anti-ER drugs.
    Gorska-Arcisz M; Popeda M; Braun M; Piasecka D; Nowak JI; Kitowska K; Stasilojc G; Okroj M; Romanska HM; Sadej R
    Cell Mol Biol Lett; 2024 May; 29(1):71. PubMed ID: 38745155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independence of HIF1a and androgen signaling pathways in prostate cancer.
    Tran MGB; Bibby BAS; Yang L; Lo F; Warren AY; Shukla D; Osborne M; Hadfield J; Carroll T; Stark R; Scott H; Ramos-Montoya A; Massie C; Maxwell P; West CML; Mills IG; Neal DE
    BMC Cancer; 2020 May; 20(1):469. PubMed ID: 32450824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.
    Neuwirt H; Bouchal J; Kharaishvili G; Ploner C; Jöhrer K; Pitterl F; Weber A; Klocker H; Eder IE
    Cell Commun Signal; 2020 Jan; 18(1):11. PubMed ID: 31980029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer.
    Bahnassy S; Thangavel H; Quttina M; Khan AF; Dhanyalayam D; Ritho J; Karami S; Ren J; Bawa-Khalfe T
    Cell Commun Signal; 2020 Sep; 18(1):154. PubMed ID: 32948192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p62/SQSTM1 is required for cell survival of apoptosis-resistant bone metastatic prostate cancer cell lines.
    Chang MA; Morgado M; Warren CR; Hinton CV; Farach-Carson MC; Delk NA
    Prostate; 2014 Feb; 74(2):149-63. PubMed ID: 24122957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.
    Asim M; Massie CE; Orafidiya F; Pértega-Gomes N; Warren AY; Esmaeili M; Selth LA; Zecchini HI; Luko K; Qureshi A; Baridi A; Menon S; Madhu B; Escriu C; Lyons S; Vowler SL; Zecchini VR; Shaw G; Hessenkemper W; Russell R; Mohammed H; Stefanos N; Lynch AG; Grigorenko E; D'Santos C; Taylor C; Lamb A; Sriranjan R; Yang J; Stark R; Dehm SM; Rennie PS; Carroll JS; Griffiths JR; Tavaré S; Mills IG; McEwan IJ; Baniahmad A; Tilley WD; Neal DE
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26657335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The selective inhibitory effect of a synthetic tanshinone derivative on prostate cancer cells.
    Xu D; Lin TH; Zhang C; Tsai YC; Li S; Zhang J; Yin M; Yeh S; Chang C
    Prostate; 2012 May; 72(7):803-16. PubMed ID: 21932429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.